O-RADS超声联合CA-125能否提高不同绝经状态女性附件肿物恶性风险诊断准确性
该回顾性研究纳入2018年1月至2020年1月因附件肿物拟手术的443例患者(443个病灶,良性312个、恶性131个;绝经前361例、绝经后82例),评估O-RADS超声与CA-125单独及联合诊断效能。两位放射科医生间一致性很好(加权κ=0.833)。O-RADS联合CA-125较单用O-RADS显著提高鉴别良恶性的准确性(绝经前AUC 0.97 vs 0.95,P<.001;绝经后AUC 0.93 vs 0.85,P<.001)。
要点
- O-RADS联合CA-125较单用O-RADS显著提高附件肿物良恶性鉴别准确性(绝经前AUC 0.97 vs 0.95,绝经后AUC 0.93 vs 0.85,均P<.001)。
- 联合CA-125对绝经后女性的提升更明显(AUC 0.85升至0.93)。
- 两位放射科医生O-RADS评估一致性很好(加权κ=0.833)。
核心结论
- 加入CA-125有助于提高O-RADS超声鉴别附件肿物良恶性的能力,尤其在绝经后女性中。
研究设计与样本
- 回顾性研究,纳入2018年1月至2020年1月因附件肿物拟手术、有术前超声和组织病理结果的患者443例(443个病灶),由两位经验丰富的放射科医生进行O-RADS评估,以组织病理为参考标准。
诊断标准与关键数值
- O-RADS联合CA-125与单用O-RADS的AUC:绝经前0.97 vs 0.95(P<.001),绝经后0.93 vs 0.85(P<.001);O-RADS联合或不联合CA-125在不同附件病理亚型(良性、交界性、I-IV期、转移性肿瘤)的AUC范围为0.50至0.99。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the individual and combined performances of the Ovarian-adnexal Reporting and Data System Ultrasound (O-RADS US) and serum cancer antigen 125 (CA-125) in assessing adnexal malignancy risk in women with different menopausal status.
METHODS: This retrospective study included patients with adnexal masses scheduled for surgery based on their preoperative US and histopathology results between January 2018 and January 2020. O-RADS were used to assess adnexal malignancy by two experienced radiologists. The area under the receiver operating characteristic curves (AUCs) were used to compare the accuracy of O-RADS and a combination of O-RADS and CA-125. The weighted κ index was used to evaluate the inter-reviewer agreement.
RESULTS: Overall, the data of 443 lesions in 443 patients were included, involving 312 benign lesions and 131 malignant lesions. There were 361 premenopausal and 82 postmenopausal patients. The inter-reviewer agreement for the two radiologists was very good (weighted κ: 0.833). Combing O-RADS US and CA-125 significantly increased diagnostic accuracy for classifying malignant from benign adnexal masses, compared with O-RADS US alone (AUC: 0.97 vs 0.95, P < .001 for premenopausal population and AUC: 0.93 vs 0.85, P < .001 for postmenopausal population). The AUCs of O-RADS with and without CA-125 ranged from 0.50 to 0.99 for different adnexal pathology subtypes (ie, benign, borderline, Stage I-IV, and metastatic tumors).
CONCLUSION: The addition of CA-125 helps improve discrimination of O-RADS US between benign and malignant adnexal masses, especially in postmenopausal women.
引用
- Wu, Wang, Zhang, et al. Does Combing O-RADS US and CA-125 Improve Diagnostic Accuracy in Assessing Adnexal Malignancy Risk in Women With Different Menopausal Status? J Ultrasound Med. 2022. PMID: 35880406. doi:10.1002/jum.16065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。